340 related articles for article (PubMed ID: 24335752)
21. Solasodine inhibits invasion of human lung cancer cell through downregulation of miR-21 and MMPs expression.
Shen KH; Hung JH; Chang CW; Weng YT; Wu MJ; Chen PS
Chem Biol Interact; 2017 Apr; 268():129-135. PubMed ID: 28283413
[TBL] [Abstract][Full Text] [Related]
22. Reversion-inducing-cysteine-rich protein with Kazal motif is involved in intimal hyperplasia in carotid arteries: a new insight in the prevention of restenosis after vascular angioplasty.
Liu J; Chi D; Lu H; Zhang T; Yamakawa T
Ann Vasc Surg; 2015 Aug; 29(6):1293-9. PubMed ID: 26004948
[TBL] [Abstract][Full Text] [Related]
23. Norcantharidin enhances TIMP‑2 anti‑vasculogenic mimicry activity for human gallbladder cancers through downregulating MMP‑2 and MT1‑MMP.
Zhu W; Sun W; Zhang JT; Liu ZY; Li XP; Fan YZ
Int J Oncol; 2015 Feb; 46(2):627-40. PubMed ID: 25405519
[TBL] [Abstract][Full Text] [Related]
24. High variability in MMP2/TIMP2 and MMP9/TIMP1 expression in secondary liver tumors.
Avădanei R; Căruntu ID; Amălinei C; Lozneanu L; Balan R; Grigoraş A; Ciobanu Apostol D; Giuşcă SE
Rom J Morphol Embryol; 2013; 54(3):479-85. PubMed ID: 24068394
[TBL] [Abstract][Full Text] [Related]
25. mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor.
Scrideli CA; Cortez MA; Yunes JA; Queiróz RG; Valera ET; da Mata JF; Toledo SR; Pavoni-Ferreira P; Lee ML; Petrilli AS; Brandalise SR; Tone LG
Leuk Res; 2010 Jan; 34(1):32-7. PubMed ID: 19875168
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study.
Pietruszewska W; Bojanowska-Poźniak K; Kobos J
Otolaryngol Pol; 2016 Jun; 70(3):32-43. PubMed ID: 27386931
[TBL] [Abstract][Full Text] [Related]
27. Expression of membrane-anchored matrix metalloproteinase inhibitor reversion inducing cysteine rich protein with Kazal motifs in murine cell lines.
Takagi S; Hoshino Y; Osaki T; Okumura M; Fuginaga T
Exp Oncol; 2007 Mar; 29(1):30-4. PubMed ID: 17431385
[TBL] [Abstract][Full Text] [Related]
28. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
[TBL] [Abstract][Full Text] [Related]
29. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
30. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer.
van der Jagt MF; Sweep FC; Waas ET; Hendriks T; Ruers TJ; Merry AH; Wobbes T; Span PN
Cancer Lett; 2006 Jun; 237(2):289-97. PubMed ID: 16046057
[TBL] [Abstract][Full Text] [Related]
31. Calcifying Cystic Odontogenic Tumour: immunohistochemical expression of matrix metalloproteinases, their inhibitors (TIMPs and RECK) and inducer (EMMPRIN).
Prosdócimi FC; Rodini CO; Sogayar MC; Sousa SC; Xavier FC; Paiva KB
J Oral Pathol Med; 2014 Aug; 43(7):545-53. PubMed ID: 24484176
[TBL] [Abstract][Full Text] [Related]
32. Potential Role of Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs (RECK) in Regulation of Matrix Metalloproteinases (MMPs) Expression in Periodontal Diseases.
Liu N; Zhou B; Zhu G
Med Sci Monit; 2016 Jun; 22():1936-8. PubMed ID: 27272560
[TBL] [Abstract][Full Text] [Related]
33. The RECK gene and biological malignancy--its significance in angiogenesis and inhibition of matrix metalloproteinases.
Alexius-Lindgren M; Andersson E; Lindstedt I; Engström W
Anticancer Res; 2014 Aug; 34(8):3867-73. PubMed ID: 25075007
[TBL] [Abstract][Full Text] [Related]
34. Reduced Expression of RECK Protein May Help Differentiate Cutaneous Malignant Melanoma from Melanocytic Nevus.
Zhang L; Xie Q; Shan SJ; Tabor MK; Junkins-Hopkins JM
Anticancer Res; 2015 Jun; 35(6):3185-91. PubMed ID: 26026078
[TBL] [Abstract][Full Text] [Related]
35. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.
Masui T; Doi R; Koshiba T; Fujimoto K; Tsuji S; Nakajima S; Koizumi M; Toyoda E; Tulachan S; Ito D; Kami K; Mori T; Wada M; Noda M; Imamura M
Clin Cancer Res; 2003 May; 9(5):1779-84. PubMed ID: 12738734
[TBL] [Abstract][Full Text] [Related]
36. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation.
Hofmann UB; Eggert AA; Blass K; Bröcker EB; Becker JC
Cancer Res; 2003 Dec; 63(23):8221-5. PubMed ID: 14678978
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-15a promotes neuroblastoma migration by targeting reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and regulating matrix metalloproteinase-9 expression.
Xin C; Buhe B; Hongting L; Chuanmin Y; Xiwei H; Hong Z; Lulu H; Qian D; Renjie W
FEBS J; 2013 Feb; 280(3):855-66. PubMed ID: 23176145
[TBL] [Abstract][Full Text] [Related]
38. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
39. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
[TBL] [Abstract][Full Text] [Related]
40. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Kim HJ; Park CI; Park BW; Lee HD; Jung WH
Yonsei Med J; 2006 Jun; 47(3):333-42. PubMed ID: 16807982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
